ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2006
The future of antisense oligonucleotides in the treatment of respiratory diseases.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Scavenger receptor-mediated lung-targeted delivery of anti-miR-155 oligoDNA nanomicelles with curcumin for acute lung injury therapy.Asian journal of pharmaceutical sciences · 2026Article
- Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.Pharmaceutics · 2023Review
- Hydrogel armed with Bmp2 mRNA-enriched exosomes enhances bone regeneration.Journal of nanobiotechnology · 2023Article
- Mechanisms of Antisense Transcription Initiation with Implications in Gene Expression, Genomic Integrity and Disease Pathogenesis.Non-coding RNA · 2019Review
- Delivery of oligonucleotides with lipid nanoparticles.Advanced drug delivery reviews · 2015Review
- Mechanisms of antisense transcription initiation from the 3' end of the GAL10 coding sequence in vivo.Molecular and cellular biology · 2013Article
- The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA.Cellular & molecular biology letters · 2008Article
- Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).Biologics : targets & therapy · 2007Article
- A review of antisense therapeutic interventions for molecular biological targets in asthma.Biologics : targets & therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antisense oligonucleotides (ASO) are short synthetic DNA molecules designed to inhibit translation of a targeted gene to protein via interaction with messenger RNA. More recently, small interfering (si)RNA have been developed as potent tools to specifically inhibit gene expression. ASO directed against signaling molecules, cytokine receptors, and transcription factors involved in allergic immune and inflammatory responses, have been applied in experimental models of asthma and demonstrate potential as therapeutics. Several ASO-based drugs directed against oncogenes have been developed for therapy of lung cancer, and some have recently reached clinical trials. ASO and siRNA to respiratory syncytial virus infection have demonstrated good potential to treat this condition, particularly in combination with an antiviral drug. Although ASO-based therapeutics are promising for lung diseases, issues of specificity, identification of correct molecular targets, delivery and carrier systems, as well as potential adverse effects must be carefully evaluated before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.